Verition Fund Management LLC Buys 134,739 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Verition Fund Management LLC grew its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 1,198.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 145,985 shares of the biotechnology company's stock after buying an additional 134,739 shares during the period. Verition Fund Management LLC owned approximately 0.06% of ADMA Biologics worth $2,918,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. D. E. Shaw & Co. Inc. increased its position in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock worth $76,298,000 after purchasing an additional 1,442,799 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Driehaus Capital Management LLC lifted its position in shares of ADMA Biologics by 17.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company's stock worth $33,860,000 after buying an additional 447,743 shares during the last quarter. Renaissance Technologies LLC boosted its stake in ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company's stock valued at $28,868,000 after buying an additional 575,100 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in ADMA Biologics by 11.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company's stock valued at $48,007,000 after acquiring an additional 249,412 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Transactions at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.70% of the company's stock.

ADMA Biologics Trading Down 2.6 %

ADMA stock traded down $0.52 during mid-day trading on Thursday, reaching $19.43. The company's stock had a trading volume of 1,089,070 shares, compared to its average volume of 3,610,368. The company has a market cap of $4.59 billion, a price-to-earnings ratio of 71.25 and a beta of 0.70. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The business's 50 day moving average price is $19.09 and its 200 day moving average price is $15.58. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the company earned $0.01 EPS. On average, equities research analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Analyst Ratings Changes

ADMA has been the topic of a number of research analyst reports. HC Wainwright raised their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James lifted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.